Back

Understanding and overcoming innate and acquired MAPK-inhibition resistance in anaplastic thyroid cancer

2024-12-05 oncology Title + abstract only
View on medRxiv
Show abstract

Anaplastic thyroid cancer (ATC) is one of the most lethal human cancers, with some patients succumbing to the disease within weeks of diagnosis. Although a subset of patients with ATC with BRAFV600E mutation respond to the monomeric type I RAF inhibitor (RAFi) dabrafenib in combination with MEK inhibitor (MEKi) trametinib, most rapidly develop adaptive or acquired resistance. These patients, along with those who do not harbor the BRAFV600E alteration, have limited treatment options. To understan...

Predicted journal destinations